Mechanisms of drug-eluting stent restenosis
- PMID: 33222019
- DOI: 10.1007/s12928-020-00734-7
Mechanisms of drug-eluting stent restenosis
Abstract
Drug-eluting stents (DES) were developed to overcome in-stent restenosis (ISR), which has long been considered the main complication limiting the long-term efficacy of coronary stenting. New-generation DES which composed of advanced stent design with and without specific biocompatible polymer contributes a reduction of the incidence of ISR to rate ranging from 5 to 10%. The precise reasons of DES restenosis are still controversial and not fully understood. Angiographic and coronary images at the index procedure, systemic status of patients, medications, and intracoronary imaging at ISR site are all considered to find the possible mechanisms of DES restenosis. Multiple biological, genetic, mechanical, and technical factors might intricately contribute to DES restenosis. Biological and genetic factors of ISR are not able to be sufficiently modified by the current medical approaches. Tailored treatments avoiding mechanical and technical factors of ISR are required to reduce DES restenosis. Elucidation of DES restenosis leads to further improvement in the current DES system and finds the optimal approach to treat DES restenosis. The possible mechanisms of DES restenosis are discussed in this review.
Keywords: Mechanism; Restenosis; Stent.
Similar articles
-
Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis.Int J Cardiovasc Imaging. 2020 Feb;36(2):171-178. doi: 10.1007/s10554-019-01681-y. Epub 2020 Jan 9. Int J Cardiovasc Imaging. 2020. PMID: 31919705
-
Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).JACC Cardiovasc Interv. 2015 Nov;8(13):1695-700. doi: 10.1016/j.jcin.2015.07.023. JACC Cardiovasc Interv. 2015. PMID: 26476609 Clinical Trial.
-
Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.J Am Coll Cardiol. 2015 Jul 7;66(1):14-22. doi: 10.1016/j.jacc.2015.05.002. J Am Coll Cardiol. 2015. PMID: 26139053
-
Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.Catheter Cardiovasc Interv. 2018 Aug 1;92(2):285-299. doi: 10.1002/ccd.27359. Epub 2017 Oct 10. Catheter Cardiovasc Interv. 2018. PMID: 29024274
-
Management of drug-eluting stent restenosis.J Invasive Cardiol. 2012 Apr;24(4):178-82. J Invasive Cardiol. 2012. PMID: 22477755 Review.
Cited by
-
Additional ablation effect of low-speed rotational atherectomy following high-speed rotational atherectomy on early calcified in-stent restenosis: A case report.Clin Case Rep. 2021 Jul 21;9(7):e04550. doi: 10.1002/ccr3.4550. eCollection 2021 Jul. Clin Case Rep. 2021. PMID: 34306704 Free PMC article.
-
Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.Rev Cardiovasc Med. 2024 Dec 24;25(12):458. doi: 10.31083/j.rcm2512458. eCollection 2024 Dec. Rev Cardiovasc Med. 2024. PMID: 39742219 Free PMC article.
-
Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1.J Biomed Sci. 2024 Sep 5;31(1):88. doi: 10.1186/s12929-024-01076-9. J Biomed Sci. 2024. PMID: 39237902 Free PMC article.
-
Long-term clinical outcomes of Chinese diabetic patients after coronary revascularization with drug-eluting stents: a retrospective comparative cohort study.Ann Transl Med. 2022 Nov;10(22):1206. doi: 10.21037/atm-22-4517. Ann Transl Med. 2022. PMID: 36544638 Free PMC article.
-
An Overview of Clinical Examinations in the Evaluation and Assessment of Arterial and Venous Insufficiency Wounds.Diagnostics (Basel). 2023 Jul 27;13(15):2494. doi: 10.3390/diagnostics13152494. Diagnostics (Basel). 2023. PMID: 37568858 Free PMC article. Review.
References
-
- Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483–95. - PubMed
-
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80. - PubMed
-
- Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–46. - PubMed
-
- Aoki J, Kozuma K, Awata M, Nanasato M, Shiode N, Tanabe K, et al. Three-year clinical outcomes of everolimus-eluting stents from the post-marketing surveillance study of cobalt-chromium everolimus-eluting stent (XIENCE V/PROMUS) in Japan. Circ J. 2016;80:906–12. - PubMed
-
- Kozuma K, Kimura T, Kadota K, Suwa S, Kimura K, Iwabuchi M, et al. Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET). Cardiovasc Interv Ther. 2013;28:344–51. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources